echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sanofi and Baidu collaborate to develop mRNA vaccines and partner with Owkin to deploy AI pharmaceuticals

    Sanofi and Baidu collaborate to develop mRNA vaccines and partner with Owkin to deploy AI pharmaceuticals

    • Last Update: 2022-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    Recently, Sanofi reached two collaborations to develop new therapies for 4 specific types of cancers (non-small cell lung cancer, triple-negative breast cancer, mesothelioma, and multiple myeloma) with Owkin; obtained Baidu mRNA sequence design Algorithm (LinearDesign technology) for the design of vaccines and therapeutic products
    .

    Cooperate with Baidu to develop mRNA vaccine

    Cooperate with Baidu to develop mRNA vaccine

    On November 22, Baidu announced that it had licensed the LinearDesign technology to Sanofi, France, for the design of vaccines and therapeutic products
    .
    This is the first time that Baidu has reached such a commercial agreement with a global pharmaceutical giant

    .

    According to the agreement, Baidu licenses Sanofi to use its mRNA sequence design algorithm LinearDesign technology for mRNA vaccine and drug development
    .
    Baidu will receive corresponding milestone payments, etc.
    The specific amount has not been disclosed

    .

    LinearDesign uses a dynamic programming algorithm to design the most stable COVID-19 vaccine sequence within 10 minutes, while optimizing sequence stability and protein expression to improve vaccine effectiveness
    .
    Animal experiments have shown that the sequence stability of the new crown vaccine designed by LinearDesign is greatly improved, and the antibody titer is 20 times that of the vaccine company's baseline sequence

    .
    LinearDesign also be used to develop vaccines other infectious diseases, cancer therapy and the like

    .

    It is worth noting that on October 11 this year, Baidu and Si Microbiology used the new algorithm LinearDesign to optimize the new crown mRNA vaccine sequence research has been published in the preprint journal arXiv
    .
    The optimized new coronavirus mRNA vaccine has completed preclinical research

    .

    With the outbreak of the new crown epidemic, vaccine giant Sanofi lags behind BioNTech/Pfizer and Moderna in the development of new crown mRNA vaccines
    .
    In September of this year, Sanofi announced that it would stop the mRNA new crown vaccine trial and instead focus on the recombinant protein candidate new crown vaccine with GSK

    .
    Sanofi said it will focus its mRNA resources on other diseases where the needs are not met

    .

    Hand in hand with Owkin to lay out AI pharmacy

    Hand in hand with Owkin to lay out AI pharmacy

    On November 18, Sanofi announced that it has reached a cooperation with AI and precision medicine company Owkin to develop new therapies for 4 specific types of cancer (non-small cell lung cancer, triple negative breast cancer, mesothelioma, and multiple myeloma) , While establishing a powerful disease model
    .

    According to the terms of the agreement, Sanofi will make a US$180 million equity investment in Owkin and pay US$90 million within 3 years.
    Owkin is also eligible for additional research miles

    .
    Based on this cooperation, Sanofi will use Owkin's platform to discover new biomarkers and therapeutic targets and establish a prognostic model

    .
    Similarly, Sanofi’s investment will also support Owkin to build a world-leading histological and genomic cancer database

    .

    Owkin was established in 2016.
    It connects doctors, researchers, data scientists, pharmaceutical companies, etc.
    through the platform, and uses AI technology to create data sets, and then sends the information to those in need.
    It has established best-in-class predictive biology Medical AI models and stable data sets

    .
    Its platform can collect biomedical images, genomics research and clinical data to help medical workers understand the reasons why the efficacy of drugs varies from patient to patient, improve the drug development process, and identify drugs that are more suitable for patients to improve treatment effects

    .

    In order to protect privacy and accelerate medical research with AI, Owkin has established a global research network driven by joint learning, which allows data scientists to securely connect decentralized multi-party data and build AI models without the need to aggregate data
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.